Pero tampoco lo necesitas
(2024, December 17)
Ongoing Continuous care & support 1:1 medical support throughout your journey
Stepping back a tier and spending two extra months building tolerance before re-escalating produces better long-term outcomes than powering through three weeks of daily nausea
Eli Lilly have a new, once-monthly GLP1/GIP agonist (Brenipatide) and they're running some fascinating trials with it Smoking cessation, bipolar disorder, schizophrenia, opioid use disorder, depression, alcohol use disorder, and asthma Eli Lilly have a new, once-monthly GLP1/GIP agonist (Brenipatide) and they're running some fascinating trials with it Smoking cessation, bipolar disorder, schizophrenia, opioid use disorder, depression, alcohol use disorder, and asthma That it's dosed monthly probably makes it better suited to psychiatry/addiction settings, where adherence matters a lot I made the table with some inspiration from Lilly's investor deck: investor.lilly.com/static-files/4 I bet if we treated homeless people with this, you would see a massive improvement Join the conversation
In ovo injection has the possibility to change bacterial composition in GIT short-term and long-term and influence its developmental process
